Research Analysts Issue Forecasts for Infinity Pharmaceuticals Inc.’s FY2019 Earnings (INFI)
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) – Equities researchers at FBR & Co upped their FY2019 EPS estimates for shares of Infinity Pharmaceuticals in a note issued to investors on Thursday. FBR & Co analyst C. James now expects that the firm will post earnings per share of $0.39 for the year, up from their prior forecast of $0.34. FBR & Co currently has a “Hold” rating on the stock. FBR & Co also issued estimates for Infinity Pharmaceuticals’ FY2020 earnings at $0.77 EPS.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings data on Wednesday, November 9th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.47. Infinity Pharmaceuticals had a net margin of 13.23% and a negative return on equity of 125.20%. During the same quarter last year, the company earned $0.84 EPS.
Other analysts have also recently issued research reports about the stock. Wedbush reissued a “neutral” rating and issued a $1.00 price objective (down previously from $1.25) on shares of Infinity Pharmaceuticals in a research note on Tuesday, August 9th. Morgan Stanley reissued a “hold” rating and issued a $1.00 price objective on shares of Infinity Pharmaceuticals in a research note on Thursday, August 11th. Zacks Investment Research raised shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research note on Tuesday, October 18th. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of Infinity Pharmaceuticals in a research note on Thursday, November 10th. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Infinity Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $4.56.
Shares of Infinity Pharmaceuticals (NASDAQ:INFI) traded down 3.23% during trading on Monday, hitting $1.20. 447,236 shares of the stock traded hands. The firm’s market cap is $59.67 million. The company has a 50 day moving average price of $1.34 and a 200 day moving average price of $2.25. Infinity Pharmaceuticals has a 12 month low of $0.84 and a 12 month high of $8.98.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bellevue Group AG bought a new position in Infinity Pharmaceuticals during the first quarter worth $843,000. Bank of New York Mellon Corp increased its position in Infinity Pharmaceuticals by 4.0% in the second quarter. Bank of New York Mellon Corp now owns 254,019 shares of the company’s stock worth $336,000 after buying an additional 9,876 shares in the last quarter. BVF Inc. IL bought a new position in Infinity Pharmaceuticals during the second quarter worth $6,896,000. Deerfield Management Co. increased its position in Infinity Pharmaceuticals by 2.2% in the first quarter. Deerfield Management Co. now owns 4,398,862 shares of the company’s stock worth $23,182,000 after buying an additional 93,574 shares in the last quarter. Finally, I.G. Investment Management LTD. bought a new position in Infinity Pharmaceuticals during the second quarter worth $931,000. 79.61% of the stock is owned by hedge funds and other institutional investors.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Stock Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.